GlassScriptPhysician profile
Scott G Green
NPI 1760454821
$55,508.68
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $8,872 · 2021: $5,457.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,275.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $5,134.54 | 2019 | |
| Sun Pharmaceutical Industries INC. | $3,427.65 | 2019-2021 | |
| Celgene Corporation | $1,360.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $113.38 | 2019 | |
| Ucb, INC. | $63.03 | 2019 | |
| Amgen INC. | $53.52 | 2019 | |
| Janssen Biotech, INC. | $34.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.00 | 2019 | |
| Lilly USA, LLC | $15.47 | 2019 | |
| Pfizer INC. | $15.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.